Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 0 (0%) Market Cap: 275.10 Mil Enterprise Value: 126.27 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 50/100

Q1 2024 Lexicon Pharmaceuticals Inc Earnings Call Transcript

May 02, 2024 / 09:00PM GMT
Release Date Price: €4.1
Operator

Good day, everyone, and welcome to the Lexicon Pharmaceuticals's first-quarter 2024 financial results conference call. (Operator Instructions) As a reminder, this call is being recorded today, May 2, 2024.

I will now turn the call over to Lisa DeFrancesco, Head of Investor Relations and Strategy for Lexicon. Please go ahead, Lisa.

Lisa DeFrancesco
Lexicon Pharmaceuticals Inc - Head, Investor Relations and Strategy

Thank you, Jamie, and good afternoon and welcome to the Lexicon Pharmaceuticals's first-quarter 2024 financial results conference call. Joining me today are Lonnel Coats, Lexicon's Chief Executive Officer and Director; Jeff Wade, Lexicon's President and Chief Financial Officer; Dr. Craig Granowitz, Lexicon's Senior Vice President and Chief Medical Officer; and Tom Garner, Lexicon's Senior Vice President and Chief Commercial Officer.

Earlier this afternoon, Lexicon issued a press release announcing financial results for the first quarter of 2024, which is available on our website at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot